Peer-influenced content. Sources you trust. No registration required. This is HCN.
NEJM Evidence
This study urges a re-evaluation of surrogate endpoints in advanced prostate cancer, questioning the validity of commonly used markers and calling for further research in predicting overall survival.
Oncology, Medical July 18th 2023
UT Southwestern Medical Center
The discovery of lactate’s potential to rejuvenate immune cells and combat cancer opens up exciting new avenues in the field of immunotherapy. Dive in to uncover how a simple metabolic byproduct could drastically reshape cancer treatment strategies.
Hematology/Oncology July 18th 2023
Mayo Clinic
Take part in an engaging multidisciplinary discussion on the evolving dynamics of hepato-pancreatico-biliary cancers. Discover, learn, and prepare to integrate these new strategies into your clinical practice.
Dana-Farber Cancer Institute
Gain insight into how a shift in cellular environment and UV radiation exposure can instigate additional mutations, deepening our understanding of the evolution and development of rare and complex malignancies such as BPDCN.
Dermatology July 18th 2023
Cancer Therapy Advisor
Second-generation androgen receptor pathway inhibitors (ARPIs) have proven to be essential in managing nonmetastatic castration-resistant prostate cancer (nmCRPC). These treatments provide hope in delaying metastasis and improving overall survival, significantly altering the disease’s prognosis.
OBR Oncology
ASCO and SGO have taken a proactive stance on the chemotherapy drug shortage, issuing comprehensive guidelines to aid physicians in treating six specific cancers, ensuring that the crisis does not impede effective patient care.
Oncology, Medical July 10th 2023